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We examined the leukemic stem cell potential of blasts at different stages of maturation in childhood acute
lymphoblastic leukemia (ALL). Human leukemic bone marrow was transplanted intrafemorally into NOD/scid
mice. Cells sorted using the B precursor differentiation markers CD19, CD20, and CD34 were isolated from
patient samples and engrafted mice before serial transplantation into primary or subsequent (up to quater-
nary) recipients. Surprisingly, blasts representative of all of the different maturational stages were able to re-
constitute and reestablish the complete leukemic phenotype in vivo. Sorted blast populations mirrored nor-
mal B precursor cells with transcription of a number of stage-appropriate genes. These observations inform
a model for leukemia-propagating stem cells in childhood ALL.INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most frequent malig-
nancy of childhood. Despite its overall good response to current
treatment protocols and an approximately 80% long-term event-
free survival rate (Pui, 2000), there is great demand for new ther-
apies for patients with high-risk and relapsed ALL with a cure rate
below 50%.
There is an ongoing debate as to the existence of rare cancer
stem cell populations (Clarke et al., 2006; Kelly et al., 2007;
Kennedy et al., 2007; Adams et al., 2007), which, if they exist,
would provide a key target for novel curative therapies. The
presence of leukemic stem cells has been clearly defined in
acute myeloid leukemia (AML) by xenotransplantation studies.It has been demonstrated that cells with the ability to reestab-
lish human leukemia in nonobese diabetic/severe combined
immunodeficiency (NOD/scid) mice are exclusively present
within the CD34+CD38 stem cell fraction (Lapidot et al.,
1994; Bonnet and Dick, 1997). Like the normal hematopoietic
stem cell compartment, the leukemic stem cell compartment
in AML is heterogeneous and organized as a hierarchy with dis-
tinct subclasses that differ in their proliferative and self-renewal
capacities. With a clonal tracking approach and serial trans-
plantation of candidate leukemic stem cells, it has been possi-
ble to define short-term, long-term, and quiescent long-term
leukemic stem cells within this hierarchy (Hope et al., 2004).
These profound similarities between normal and leukemic he-
matopoietic stem cells support the hypothesis that AML arisesSIGNIFICANCE
There is an ongoing debate as to whether all malignancies are maintained by a small population of immature cancer stem
cells (as for myeloid leukemias) or whether themajority of malignant cells possess some ‘‘stemness.’’ This question is of key
clinical relevance, as in vivo clonogenic stem cells constitute the primary therapeutic target. We have developed an in vivo
assay permitting the analysis of the stem cell potential of human acute lymphoblastic leukemia (ALL) blasts at different
stages of maturation. Using this approach, we demonstrate that B precursor blasts mirroring different stages of maturation
display self-renewal and possess malleability within their altered B cell developmental program. Thus, leukemic lymphoid
progenitors may not lose their self-renewal capability with maturation.Cancer Cell 14, 47–58, July 2008 ª2008 Elsevier Inc. 47
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similar to normal hematopoiesis.
For ALL, the picture is less clear. Our understanding of the hi-
erarchy of childhood B precursor ALL has been limited by the
lack of appropriate in vitro and in vivo models. The original hy-
pothesis, as proposed by Mel Greaves, suggested that the suc-
cess of treatment for childhood ALL is linked to the transforma-
tion of a B cell progenitor prone to undergo apoptosis (Greaves,
1993). In contrast, adult and certain types of high-risk ALL may
originate in a more primitive stem cell equipped with multiple
protective mechanisms to resist chemotherapy. This hypothesis
is supported by studies showing that in the most common sub-
type of childhood ALL, ALL/t(12;21), blasts and preleukemic
stem cells harboring t(12;21) are found exclusively in the more
mature CD19+ population (Hotfilder et al., 2002; Castor et al.,
2005; Hong et al., 2008). Similarly, in high-hyperdiploid ALL,
the hyperdiploidy is restricted to lymphoid cells (Kasprzyk
et al., 1999). However, the identification of leukemic subclones
with unrelated rearrangements of the diversity (D) and joining
(J) segments (Stankovic et al., 2000) and of diagnostic cytoge-
netic abnormalities in lineage marker-negative cells (Quijano
et al., 1997) argues for involvement of more primitive cells in
certain ALL patients. Moreover, involvement of immature
CD34+CD19 cells in two types of high-risk ALL, namely infant
ALL with a translocation t(4;11) and Philadelphia chromosome-
positive ALL (Hotfilder et al., 2005; Castor et al., 2005), highlights
the heterogeneity of ALL.
Most importantly, there is a paucity of functional in vivo studies
showing successful engraftment of ALL subpopulations in
immunodeficient mice. The studies published to date have
presented heterogeneous results. In two studies, only cells
with an immature stem cell-like immunophenotype (either
CD34+CD38 or CD34+CD19) were able to engraft and reiniti-
ate the leukemia in immunodeficient mice following intravenous
injection (Cobaleda et al., 2000; Cox et al., 2004), while two more
recent studies demonstrated engraftment of more mature
CD19+ lymphoid blasts rather than immature CD19 cells (Cas-
tor et al., 2005; Hong et al., 2008).
These conflicting results indicate that key questions regarding
leukemic stem cells in ALL remain unresolved. In which cell does
childhood ALL arise? Is there heterogeneity of stem cell involve-
ment in ALL? What is the phenotype of the in vivo propagating
leukemic stem cells? Is it a rare cell with a primitive immunophe-
notype, or do the majority of blasts retain some ‘‘stemness’’? The
aim of this study was to develop a more sensitive and consistent
functional assay for self-renewing candidate ALL stem cell pop-
ulations. Sorted blasts mirroring different stages of B cell matu-
ration were able to fully reconstitute and maintain the human
leukemia through serial transplantations. These populations
also express a number of stage-appropriate B cell developmen-
tal genes.
RESULTS
Flow-Sorted ALL Cells Serially Engraft NOD/scid Mice
Following Intrafemoral Injection
To establish a sensitive in vivo assay for self-renewing leukemic
stem cell populations, unmanipulated and flow-sorted bone
marrow cells from 13 children with ALL were transplanted via48 Cancer Cell 14, 47–58, July 2008 ª2008 Elsevier Inc.intrafemoral injection into NOD/scid mice, and engrafting leuke-
mias were serially transplanted into secondary, tertiary, and qua-
ternary recipients. Seven leukemias were classified as high-risk
ALL, and the remaining six leukemias were from standard-risk
patients (see the Supplemental Experimental Procedures avail-
able online). Overall, cells from 6 out of 7 high-risk (86%) and
2 out of 6 standard-risk (33%) leukemias engrafted. The eight
engrafting leukemias were serially transplanted in 199 mice. Of
the 185 mice that received at least the minimally engrafting cell
dose of 2 3 103 cells (see below), 115 (62%) showed engraft-
ment with more than 5% human leukemic blasts in the bone mar-
row, and 112 (61%) developed overt leukemia with 20%–100%
blasts (mean = 89%, SD = 18%).
The Leukemia in the Mice Recapitulates the Original
Disease within the Patient and Remains Stable through
Four Serial Transplantations
To confirm that our mouse model recapitulates the original dis-
ease, a thorough morphological, flow cytometric, and molecular
analysis of the human leukemias in the mice was performed. Hu-
man leukemic engraftment was assessed and quantified by flow
cytometric analysis of cells within the lymphocyte gate (scatter
profile) expressing CD19, CD34, and CD45. A representative
comparison of the initial and posttransplantation blasts demon-
strates a conserved immunophenotype (Figure S1). In all mice
analyzed, the human cells had a B cell precursor phenotype con-
sistent with the original diagnosis. Consistent with the flow
cytometry data, bone marrow from leukemic mice showed
a massive infiltration of mainly L1 lymphoblasts. Both of these
findings remained stable from primary to quaternary transplants
(Figure 1). Engraftment of human cells also correlated with the
development of splenomegaly, indicating that transplanted
mice developed overt leukemia (Figure S2).
Engrafted Human Cells Express the Immunophenotype
and Carry the Genetic Markers of the Original Leukemia
As engraftment of normal human myeloid cells is dependent on
pretransplant conditioning of the mice by irradiation (except for
the transplantation of very high cell doses), coengraftment of nor-
mal human hematopoietic cells was not expected in our nonirra-
diated recipient mice (Spiegel et al., 2004). This was confirmed by
flow cytometry, which failed to detect human B lineage-negative
cells expressing the myeloid markers CD33 or CD15 (Figure S1).
To molecularly confirm engraftment of leukemic rather than nor-
mal lymphoid progenitor cells, the proportion of leukemic cells
within the different human subpopulations in the mice was quan-
tified with fluorescence in situ hybridization (FISH) probes that
detect the leukemia-specific aberrations. Twenty-one leukemic
mice transplanted with samples containing the following chromo-
somal aberrations were selected for this analysis: t(4;11), t(11;19),
dup(21q), and t(12;21). Human CD34+CD19, CD34+CD19+, and
CD34CD19+ cell populations were purified from the marrow of
engrafted mice by flow sorting these cells directly onto glass
slides. The leukemia-specific chromosomal aberration could be
detected in the majority of human cells at a mean frequency of
85% (SD = 12.0%) in each cell fraction (Table 1; Figure S3A).
As the cells sorted directly onto the slides were not always nicely
spread and were sometimes slightly damaged, FISH analysis
was likely to underestimate the percentage of aberrant cells.
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Malignant Stem Cells in Childhood ALLFigure 1. The Morphology and Immunophenotype of the Leukemic Blasts Remain Stable for Four Passages in the Mice
(A) Original patient #14 blast cell morphology and immunophenotype.
(B–E) Bone marrow samples derived from mice serially transplanted with CD34+CD19+ cells from the patient shown in (A). Blast cell morphology and immuno-
phenotype resemble the original patient sample in all four consecutive transplantations.
Scale bars = 10 mm.To confirmthe leukemic nature of humanengraftments from pa-
tient samples without a known chromosomal marker, we analyzed
unsorted bone marrow of 26 leukemic mice by PCR to detect and
quantify patient-specific clonal immunoglobulin heavy chain gene
rearrangements. These rearrangements had already been estab-
lished as a feasible minimal residual disease (MRD) marker within
the patient bone marrow after initial diagnosis (#1075/04, Vd2-
Dd3 and VH1.2-JH4b; #1002/05, VH1.2-JH4b and DH2.15-
JH4b). We detected high MRD loads in 26 leukemic mouse
bone marrows transplanted with cells from the two patients.
Therefore, consistent with the flow cytometric data, the molecular
analysis detects human leukemic engraftment in the mice.
Sorted CD34+CD19, CD34+CD19+, and CD34CD19+
Populations All Contain Leukemia-Initiating Cells
CD34+CD19, CD34+CD19+, and CD34CD19+ cells were pu-
rified from the primary patient sample or most often from en-
grafted primary or subsequent mice and serially transplanted
into primary, secondary, tertiary, and quaternary recipients to
identify which population would contain leukemic stem cell ac-
tivity. To our surprise, all three leukemic subpopulations had
the capacity to engraft and reconstitute the leukemia in NOD/
scid mice after intrafemoral transplantation. First, we looked
at the engraftment of sorted subpopulations from the two pa-
tients with standard-risk ALL. One patient was diagnosed
with ALL/t(12;21), an ALL subtype that is thought not to involve
the CD34+CD19 compartment (Hotfilder et al., 2002; Castor
et al., 2005). In concordance with these previous studies,
CD19+ cells from the two standard-risk ALL patients were
able to transfer the leukemia into secondary, tertiary, and qua-
ternary mice (Table 2). Interestingly, this was independent of
the expression of CD34. In contrast, two mice transplanted
with CD34+CD19 cells showed no engraftment. A similar re-
sult was seen in mice transplanted with cells from high-risk pa-
tients (Table 2): CD19+ cells, irrespective of whether they ex-
pressed CD34, were able to transfer the leukemia intorecipient mice. In addition, the more immature CD34+CD19
population was also shown to contain cells with leukemia-initi-
ating capability at high frequency. Leukemia development after
transplantation of the different subpopulations was a consistent
and reproducible finding across the 115 mice that engrafted.
The mean time to leukemia development was 11.7 weeks (SD
5.4 weeks), regardless of which population was transplanted
(Figure S4A). At the point of sacrifice, all three populations
had produced mean engraftment levels of >80% human cells
(Figure S4B).
To confirm these surprising results, independent xenograft
transplantation experiments were initiated at the Northern Insti-
tute for Cancer Research in Newcastle using ALL blasts sorted
to be CD19+CD20/low or CD19+CD20high. Eight primary and
five secondary NOD/scid IL2Rgnull mice were transplanted with
sorted blasts from two ALL patients (#L754 and #L736) and
then assessed using diagnostic bone marrow punctures taken
between 12 and 20 weeks without being sacrificed (Table 2).
Of 7 mice receiving 8 3 104 to 1 3 105 CD19+CD20/low cells,
4 showed full engraftment with 7%–34% human leukemic infil-
trates, 2 showed low levels of human cells (4%–5%), and 1 did
not engraft. One engrafted mouse was harvested and trans-
planted into secondary mice. Of 4 primary and 2 secondary
mice transplanted with 8 3 104 to 13 105 CD19+CD20high cells,
3 have shown good engraftment (8%–19% blasts), 1 shows low
levels of engraftment (2.5% blasts), and 2 died at 10 weeks post-
transplantation before engrafting (<0.1% blasts). The engraft-
ment of sorted populations again demonstrates recapitulation
of the original patient immunophenotype (Figure S5). Ten of
these thirteen mice were still alive and appeared to be in good
health at the time of manuscript submission (March 26, 2008),
and we continue to monitor their engraftment. As both
CD19+CD20/low and the more mature CD19+CD20high blasts
engraft, these data confirm our observation that leukemic blasts,
mirroring different stages of B cell maturation, display leukemic
stem cell activity.Cancer Cell 14, 47–58, July 2008 ª2008 Elsevier Inc. 49
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Patient Mouse #
Subpopulation and
Dosage
Transplantation
(Prim.-Tert.)
Final Engraftment
Level (%)
FISH-Positive Human Cells in Mouse (%)
CD34+CD19 CD34+CD19+ CD34CD19+
#14 (dup(21q)) 153 6.0 3 106 unsorted primary 96 74.1 (unsorted)
177 2.0 3 105 CD34+CD19+ secondary 98 60 84 –
179 2.0 3 105 CD34+CD19+ secondary 96 91 74 84
229 2.0 3 104 CD34+CD19+ tertiary 97 – 86 –
232 2.0 3 104 CD34+CD19+ tertiary 97 – 87 –
249 1.5 3 104 CD34+CD19 tertiary 98 – 80 –
213 3.0 3 104 CD34CD19+ tertiary 97 77 43 72
219 3.0 3 104 CD34CD19+ tertiary 99 90 80 –
#1 (t(4;11)) 51 1.0 3 105 CD34+CD19 primary 76 69 69 –
65 6.0 3 104 CD34+CD19+ secondary 97 – 75 65
#9 (t(4;11)) patient sample – – – 100 98 99
235 3.0 3 104 CD34+CD19 primary 99 89 78 80
236 2.0 3 105 CD34+CD19+ primary 99 88 88 90
239 3.0 3 104 CD34+CD19 primary 93 99 97 –
240 2.0 3 105 CD34+CD19+ primary 97 – 94 98
#15 (t(11;19)) 162 11.5 3 106 unsorted primary 93 89 95 98
202 2.0 3 106 CD34+CD19+ secondary 100 98 94 99
206 4.0 3 104 CD34CD19+ secondary 96 – 87 97
243 2.0 3 106 CD34+CD19+ tertiary 98 – 92 90
244 2.0 3 104 CD34+CD19+ tertiary 98 – 93 –
#866/06 (t(12;21)) 167 2.0 3 105 CD34CD19+ secondary 70 – 99 93
104 7.0 3 106 unsorted primary 34 – 98 93
High proportions of cells with leukemia-specific chromosomal aberrations were detected by fluorescence in situ hybridization (FISH) analysis in every
engrafted subpopulation (mean = 85.4%, SD = 12.2%). Whenever possible, two specimens per engrafted mouse bone marrow were examined. Data
represent mean values. , no data available.Of the 185 mice in the original experiments, 21 were trans-
planted with cells directly sorted from the original diagnostic
bone marrow sample (patients #1, 9, and 12) (Table S1). Primary
mice engrafted with CD34+CD19 (n = 2), CD34+CD19+ (n = 4),
and CD34CD19+ blasts (n = 3). Moreover, eight additional
Table 2. Engraftment of Populations from High-Risk and
Standard-Risk ALL, Sorted Using CD34/19 or CD19/20
Transplanted Subpopulation Transplanted Mice Engrafted Mice
Standard-risk ALL (n = 3)
CD34+CD19 2 0 (0%)
CD34+CD19+ 5 4 (80.0%)
CD34CD19+ 18 11 (61.1%)
CD19+CD20/low 3 1 (33.3%)
CD19+CD20high 2 1 (50.0%)
High-risk ALL (n = 7)
CD34+CD19 37 15 (40.5%)
CD34+CD19+ 80 58 (72.5%)
CD34CD19+ 41 27 (65.9%)
CD19+CD20/low 4 3 (75.0%)
CD19+CD20high 4 2 (50.0%)
The table summarizes all 196 mice that were transplanted with purified
ALL subpopulations from the ten engrafting leukemias (patients #1, 9,
12, 14, 15, 862/02, 1075/04, 1002/05, L736, and L754) using a minimal
cell dose of 2 3 103 cells.50 Cancer Cell 14, 47–58, July 2008 ª2008 Elsevier Inc.NOD/scid IL2Rgnull mice were transplanted in Newcastle with
13105 CD19+CD20/low or CD19+CD20high blasts directly sorted
from the original patient sample (patient #L754). Five of these pri-
mary mice had human leukemic blasts in the murine bone marrow
at 12 weeks after transplantation (Figure S5). We are therefore
confident that there was no difference in engraftment, whether
the cells were sorted directly from the original patient sample or
from the leukemia recovered from engrafted mice.
The Intrafemoral NOD/scid Assay Is a Highly Sensitive
and Specific Model for Engraftment of Sorted
Leukemic Populations
To evaluate the sensitivity of our mouse model, we performed
a limiting dilution assay by transplanting CD34+CD19,
CD34+CD19+, and CD34CD19+ cells from patient #12 in de-
scending concentrations into NOD/scid mice as follows.
CD34+CD19 cells: 2 mice each transplanted with 1.0 3 103,
1.0 3 102, and 1.0 3 101 cells; CD34+CD19+ and CD34CD19+
cells: 2 mice each transplanted with 1.03 104, 1.03 103, and 1.03
102 cells. None of the mice transplanted with CD34+CD19
cells and one mouse each transplanted with 1.0 3 104
CD34+CD19+ or CD34CD19+ cells engrafted. In addition, 4
out of 7 mice (57%) transplanted with 2–7 3 103 CD34+CD19
cells and 3 out of 6 mice (50%) transplanted with 1.0 3 104
CD19+ cells engrafted. Thus, a minimum cell dose of 2.0 3 103
cells was shown to be sufficient to reestablish the leukemia in
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Malignant Stem Cells in Childhood ALLFigure 2. Immunophenotypic Composition of the Leukemic Grafts in the Mice
(A) High-risk ALL. The composition of the human grafts in respect to the presence of CD34+CD19 (black), CD34+CD19+ (dark gray), and CD34CD19+ (light gray)
cells resembles that of the original leukemias shown in (C). All three subpopulations were able to reconstitute the complete phenotype of the original leukemia.
However, mice transplanted with the more mature CD34CD19+ immunophenotype engrafted with a slightly lower level of CD34+CD19 cells (0.04% versus
0.2% and 0.3%; p = 0.022) and higher levels of CD34CD19+ lymphoid cells (36% versus 6.3% and 7.4%; p % 0.001) as compared with mice transplanted
with the other two cell fractions.
(B) Standard-risk ALL. The composition of the graft was similar in mice that received CD34+CD19+ and CD34CD19+ cells. Two mice transplanted with
CD34+CD19 cells did not engraft.
(C) Distribution of the three subpopulations in the original patient samples.
Error bars show one SD (not calculated for two standard-risk patients in [C]).recipient NOD/scid mice. This compares favorably with previ-
ously published xenograft models that required a minimum of
2.0 3 104 CD34+CD38 cells (Cobaleda et al., 2000), 5.0 3 104
CD34+CD19 cells (Cox et al., 2004), or 5.5 3 105 CD19+ cells
(Castor et al., 2005) to engraft transplanted mice and confirms
the higher efficacy of intrafemoral as compared with intravenous
transplantation (Mazurier et al., 2003).
Sorted cells were reanalyzed by flow cytometry, and the pu-
rities of the populations were 95% (SD = 2.5%; n = 9) for
CD34+CD19 cells, 97% (SD = 3.5%; n = 58) for CD34+CD19+
cells, and 96% (SD = 7.0%; n = 34) for CD34CD19+ cells.
Similarly, the sort purities of the CD19+CD20/low and
CD19+CD20high blasts were above 96%. Therefore, 1 3 104
CD34+CD19+ cells with an average purity of 97% may have con-
tained 300 CD34+CD19 or CD34CD19+ cells and 2 3 103
CD34+CD19 cells with an average purity of 95% may have con-
tained only 100 CD19+ cells, well below the minimal cell number
necessary for leukemic engraftment. Table S2 summarizes those
engraftments where the maximum contaminating population
was lower than the minimally engrafting cell dose on 2.0 3 103
cells, confirming that engraftment originates from the bulk pop-
ulation and not contamination.
Flow-Sorted Populations Reestablish the Complete
Immunophenotype of the Original Leukemia
and Self-Renew
To compare the maturation and self-renewal potential of the
different candidate stem cell populations, we analyzed the com-
position of the grafts in the mice as established by these subpop-
ulations from high- and standard-risk patients (Figure 2). Thedata show that, independent of the immunophenotype of the
transplanted population, the same pattern of surface marker ex-
pression as found in the original leukemia was reestablished in
the bone marrow of leukemic mice.
Another important question was whether all three populations
retain the capacity to reestablish the complete leukemic pheno-
type in vivo over a series of sequential transplantations. Figure 3
shows a representative series of three transplantations, starting
with primary, unsorted mononuclear cells derived from patient
#1075/04, followed by subsequent transplantations of sorted
populations. This demonstrates that in both primary and subse-
quent transplants, regardless of immunophenotype of the trans-
planted population, the human leukemia in the mice very closely
recapitulates the immunophenotype in the original patient. All
three subpopulations, i.e., CD34+CD19, CD34+CD19+, and
CD34CD19+ cells, were able to engraft, proliferate, reestablish
the complete phenotype, and maintain the leukemia (self-renew)
for at least four sequential transplantations, spanning a period
ofR12 months.
Sorted Primary Blasts Retain the B Precursor
Developmental Program and Express Immunoglobulin
Transcripts in a Stage-Appropriate Manner
While B precursor populations expressing all investigated devel-
opmental surface markers are able to recapitulate the full leuke-
mic phenotype, we wanted to know whether this is representa-
tive of an underlying biological difference. Primary patient
samples were sorted by fluorescence-activated cell sorting
(FACS) to give blast populations expressing CD34+CD19+ and
CD34CD19+, with mean purity of 96.8% (SD 1.98%; data notCancer Cell 14, 47–58, July 2008 ª2008 Elsevier Inc. 51
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Each dot plot (except for the patient sample) represents one mouse engrafted with human leukemic cells. Sorting gates and arrows indicate the subpopulation
each mouse received from its predecessor. Mouse number and the exact cell dose transplanted into that mouse are provided in the heading of each dot plot.shown), for real-time RT-PCR analysis using a candidate gene
approach. Figure 4 shows that, across four patient samples,
the expression of transcription factors involved in the B precur-
sor developmental program mirrors that expected in normal B
cell development. Principally, both populations express the early
transcription factors E2A, EBF1, PAX5, and LEF1 while only the
more mature CD34CD19+ population shows a significant upre-
gulation of IRF4, a transcription factor that has a role in making
the immunoglobulin light chain loci accessible for recombination
and expression in small pre-BII cells (Ma et al., 2006).
Furthermore, genome-wide expression analysis demon-
strated that 5 of 13 genes that show >43 upregulation in the
CD34CD19+ populations are immunoglobulin loci transcripts
(Table 3). Additionally, CD20 and CD34 appropriately show upre-
gulation and downregulation, respectively, in the more mature
population.
DISCUSSION
We have been able to characterize candidate human ALL stem
cell populations by serial transplantation of flow-sorted subpop-
ulations in immunodeficient NOD/scid mice. Up to now,
progress on understanding the hierarchy of childhood B cell pre-
cursor ALL has been hampered by the lack of appropriate in vitro
and in vivo models. In vitro, only a minority of ALL leukemias are52 Cancer Cell 14, 47–58, July 2008 ª2008 Elsevier Inc.able to survive and proliferate on stromal cell cultures (Nishigaki
et al., 1997) and undergo rapid apoptosis. The few studies pub-
lished to date showing successful engraftment of ex vivo manip-
ulated subpopulations from B cell precursor ALL have yielded
conflicting results (Cobaleda et al., 2000; Cox et al., 2004; Castor
et al., 2005; Hong et al., 2008). We therefore set out to develop
a more sensitive and robust transplantation assay to define the
cell populations that are able to maintain the ALL in vivo (leuke-
mia-propagating stem cells).
As has been shown in previous studies (Lapidot et al., 1994;
Mazurier et al., 2003; Hope et al., 2004; Castor et al., 2005),
the bone marrow microenvironment appears to be sufficiently
conserved between mice and men to allow the survival and pro-
liferation of normal and leukemic human stem cell populations
that cannot be maintained in vitro. However, clinically aggressive
and relapsed leukemias grow better in immunodeficient mice
than samples from standard-risk patients (Kamel-Reid et al.,
1991; Uckun et al., 1998), and not every human leukemia is
able to engraft and proliferate in mice (Bonnet and Dick, 1997).
This may be due to the dependency of some leukemias on mi-
croenvironmental signals that are not active across species. In
accordance with this experience, we saw that cells from 6 out
of 7 high-risk (86%) but only 2 out of 6 standard-risk (33%) pa-
tients engrafted. Despite this, the NOD/scid mouse model repre-
sents the best available functional assay for candidate human
Cancer Cell
Malignant Stem Cells in Childhood ALLleukemic stem cell populations, in which there appears to be only
minimal pressure on the human cells to adapt to the murine mi-
croenvironment.
The intrafemoral NOD/scid serial transplantation assay de-
scribed in the present study provides a highly sensitive and spe-
cific assay for transplantation of ALL stem cells. It has allowed us
to achieve excellent rates of engraftment from a range of donor
blast populations without preconditioning, thus avoiding coen-
graftment of normal hematopoietic cells. Most importantly, the
constant immunophenotype and reproduction of clinical disease
over serial transplantations and many months, whether the pri-
mary transplant involved sorted or unsorted material, provides
reassurance that this assay is highly representative of the biology
of our target population.
The sequential expression of immunophenotypic markers of
B cell differentiation has been well defined (Hystad et al., 2007;
Noordzij et al., 2002). Many are present throughout much of nor-
mal B precursor development, such as CD10, CD22, and CD38.
Others can be used to define the ‘‘stages’’ of development of B
precursor cells to a greater degree: CD34 is expressed on hema-
topoietic stem cells. Downregulation follows IgH locus rear-
rangement and the appearance of cytosolic IgM heavy chain.
CD19 is a transcriptional target of PAX5, forming one of the ear-
liest, B lymphoid-restricted markers. Surface expression corre-
lates with rearrangement of VH-DJH (Zhang et al., 2006). CD20
expression is upregulated in cells undergoing rearrangement
of, or cells that have rearranged, the immunoglobulin light chain
locus (Noordzij et al., 2002; van Zelm et al., 2005). We therefore
chose to use these surface markers as a tool to identify and
purify leukemic blasts mirroring subpopulations with differing
maturation status.
Surprisingly, and in contrast to previous studies (Cobaleda
et al., 2000; Cox et al., 2004; Castor et al., 2005), we were able
to show that in high-risk ALL, each of the CD34+CD19,
CD34+CD19+, and CD34CD19+ populations was able to serially
Figure 4. Primary Patient CD34CD19+ Populations Show Signifi-
cant Upregulation of the Small Pre-B Cell-Specific Transcription
Factor IRF4
Each bar represents pooled quantitative PCR data from four (three for E2A) pa-
tient bone marrow specimens taken at diagnosis and sorted into CD34+CD19+
and CD34CD19+ blast populations. DDCt values between CD34CD19+ and
CD34+CD19+ populations have been transformed and normalized within a pa-
tient specimen against the B cell-specific transcription factor PAX5. Expres-
sion of IRF4 shows significant upregulation in the more mature CD34CD19+
population (p < 0.01). Error bars show one SD.transplant the leukemia. In keeping with previous studies show-
ing that standard-risk ALL is restricted to the CD19+ fractions
(Hotfilder et al., 2002; Castor et al., 2005; Hong et al., 2008),
low levels of CD34+CD19 cells could only be purified from
two leukemic mice and may not have constituted a real popula-
tion. As expected, these cells did not engraft subsequent mice.
In addition to propagating leukemia, each of the transplanted
fractions was able to recapitulate the complete disease immuno-
phenotype, demonstrating the ability of blasts to move back and
forth between the different populations. Again, this characteristic
was maintained over serial transplantations. These results have
been independently replicated by a separate series of experi-
ments at a second institute using CD20 as an alternative marker
of differentiation (Figure S5).
These findings raised the question of whether the immunophe-
notypically defined populations genuinely represent cells with
differing biology or whether the immunophenotype is a stochas-
tic phenomenon. The expression patterns of sorted blasts
indicate that the different populations display a pattern of B
precursor transcription factors similar to that expected in normal
B cell development, with upregulation of the late B precursor
Table 3. Microarray Analysis of CD34+CD19+ and CD34CD19+
Primary Blast Populations
Array ID
Transcript
Product
CD34:CD34+ Expression Ratio
Patient L787 Patient L812
228592_at MS4A1 (CD20) 11 92
224795_x_at Immunoglobulin k
locus
14 33
230245_s_at Hypothetical protein 4 33
221671_x_at Immunoglobulin k
locus
34 29
217022_s_at Immunoglobulin
heavy constant a
1 and 2
14 22
214677_x_at Immunoglobulin l
locus
4 16
214836_x_at Immunoglobulin k
locus
9 15
216834_at Regulator of G
protein signaling 1
10 7
237849_at Transcribed locus 5 6
233955_x_at CXXC finger 5 6 5
208178_x_at TRIO 4 4
209013_x_at TRIO 4 4
1568983_a_at cDNA clone 4 4
209543_s_at CD34 0.16 0.05
212002_at Chr 1 open
reading frame 144
0.24 0.18
243489_at Transcribed locus 0.04 0.18
Two patient bone marrow specimens taken at diagnosis and sorted by
fluorescence-activated cell sorting (FACS) using CD34 and CD19 expres-
sion show upregulation > 43 in the expression of immunoglobulin loci
IgH, Igk, and Igl. MS4A1 codes for the B cell differentiation marker
CD20 and shows upregulation. CD34 shows appropriate downregulation
in the CD34CD19+ population.Cancer Cell 14, 47–58, July 2008 ª2008 Elsevier Inc. 53
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review, see Matthias and Rolink, 2005). Furthermore, initial ex-
pression array data show that the CD34CD19+ population,
which would be expected to contain small pre-BII cells in normal
hematopoiesis, upregulates expression of immunoglobulin loci.
These findings suggest that the biology of our sorted populations
may mirror, at least in part, that of their ‘‘normal’’ hematopoietic
counterparts.
One potential concern was that serial transplantation might
lead to the selection of an in vivo cell line with an altered stem
cell biology. However, mice transplanted with cells sorted
directly from primary patient material demonstrated a consistent
pattern of engraftment over multiple passages. All populations,
defined using both CD34/CD19 (Table S1) and CD19/CD20
combinations, were able to reestablish the leukemia in mice.
Thus, there appears to be no selection process that alters the
human stem cell program during serial transplantations in the
mice.
The high sensitivity of this assay may also raise the question of
the purity of the flow-sorted cell populations. Transplantation
of limiting dilutions with known purity has shown that, for each
of the three populations, robust engraftment follows transplanta-
tion of very low cell doses at which the contaminant populations
are too small to account for the leukemic engraftment. This argues
strongly that engraftment originates from the intended popula-
tions and not from a minor, contaminating stem cell population.
Although unlikely, our study does not formally rule out that
there is a rare leukemic stem cell population present in all of
the different cell fractions. We have, however, previously shown
that CD34+CD19CD117+ cells do not appear to be part of the
leukemic clone, and CD19+CD117+ cells were not detectable
(Baersch et al., 1999). In addition, the commonly used stem
cell marker CD133 is usually not expressed on the most mature
leukemic CD34CD19+CD20+ cells (Baersch et al., 1999). Thus,
any putative rare ALL stem cell, present in all populations, could
not be characterized by the established stem cell markers CD34,
CD117, or CD133. The presence of a putative rare leukemic stem
cell population therefore seems quite unlikely, also considering
the fact that the different populations mirror normal B cell devel-
opment. Thus, the observed differences between standard- and
high-risk ALL, the consistency and reproducibility of the engraft-
ment of all subpopulations, the sensitivity of the assay, and the
purity of the flow-sorted cells all indicate that these results reflect
the biology of childhood ALL rather than being an artifact of our
model system.
In an elegant study, it has recently been shown that TEL-AML1
affects a CD19+ B lymphoid progenitor cell that has partially re-
arranged its DJH locus (Hong et al., 2008). The authors demon-
strate that preleukemic stem cells reside only in an abnormal
CD34+CD38/lowCD19+ population, previously identified in
TEL-AML1 ALL (Castor et al., 2005). However, they performed
only limited studies with three patient samples to test whether
more mature leukemic CD34+/CD38+CD19+ cells may also
have acquired this stem cell phenotype. As our experiments
only contain two engrafted mice from one patient with TEL-
AML1-positive ALL, one transplanted with CD34+CD19+ cells
and one with CD34CD19+ cells, the question of the leukemia-
propagating stem cell populations in this ALL subtype remains
unresolved. It may be that complete leukemic transformation54 Cancer Cell 14, 47–58, July 2008 ª2008 Elsevier Inc.is required for B precursors to develop their full stem cell poten-
tial. Further studies are therefore required to clarify whether, un-
like other leukemic subtypes transplanted in this study, TEL-
AML1-positive ALL displays stem cell activity only in a restricted
population.
Our in vivo data are compatible with existing data showing
a surprisingly high percentage of clonogenic cells in ALL sam-
ples (up to 20%) that are able to proliferate and self-renew in vitro
on stromal cell cultures (Nishigaki et al., 1997). Similarly, in some
murine leukemia models, a very high frequency of 1:6 leukemic
stem cells can be found (Krivtsov et al., 2006). These data are
compatible with our observation that all subpopulations, i.e.,
cell populations with an immature stem cell-like or a more mature
B cell progenitor phenotype, contain leukemia-initiating cells.
Due to the sensitivity of ALL blasts ex vivo and their tendency
to undergo apoptosis, it is likely that this in vivo assay underes-
timates the frequency of leukemic stem cells. Therefore, despite
the fact that after cell sorting, a minimum of 2 3 103 cells are
needed to achieve successful leukemic engraftment, the actual
frequency of leukemic stem cells may be higher, approaching
that observed in the stromal cell assay.
In conclusion, we have shown that leukemic blasts expressing
a range of B lineage differentiation markers are able to engraft
immunodeficient mice, reconstitute the complete leukemia phe-
notype (even cell populations expected to be less mature than
the engrafting cells), and continue to engraft further mice with
the same diverse populations over four serial transplantations
and 12 months. Furthermore, we have early evidence in support
of these populations being diverse at a transcriptome level and
appearing to mirror their ‘‘normal’’ immunophenotypic counter-
parts. From these findings, we have developed a model of B pre-
cursor ALL biology. Figure 5 shows both a schematic of normal B
precursor differentiation with the pattern of transcription factors,
immunogenetic rearrangements, and immunophenotype (A) and
B precursor ALL behavior mirroring this ‘‘normal’’ process (B).
While normal B precursor development follows a closely ordered
pattern dictated by the sequential expression of transcription
factors, we show that ALL blasts are able to move back and forth
within this narrow window of development, adopting biology mir-
roring the relevant normal populations. That all populations of
lymphoid blasts should be able to initiate a self-renewal program
is perhaps not so unexpected given the ability of both large pre-
BII cells and mature B cells to undergo clonal expansion. Thus,
this model of malleability describes biological characteristics
possessed by normal B precursor cells and therefore programs
that presumably remain relatively accessible following leukemic
transformation.
A key question remaining to be investigated is the role of im-
mature CD34+CD19 cells in drug resistance. Primitive hemato-
poietic stem cells are thought to protect themselves against DNA
damage, e.g., by expression of certain transporter proteins
(ABCB1/MDR-1/p-glycoprotein, ABCG2/BCRP) that pump
a wide variety of xenobiotic toxins out of the cells. If primitive
CD34+CD19 leukemic stem cells express the same stem cell-
associated resistance mechanisms, this may contribute to the
poor prognosis of ALL with involvement of the primitive stem
cell compartment. Even if more mature ALL blasts retain the abil-
ity to self-renew, the most primitive CD34+CD19 leukemic stem
cells may still provide a reservoir of drug-resistant stem cells
Cancer Cell
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Renewal Seen in B Precursor ALL Blasts
(A) Normal hematopoiesis. The development from
CD34+CD19 early B progenitor expressing tran-
scription factors E2A and EBF1 through to
CD34CD19+CD20+/ small pre-B cells express-
ing IRF4 and rearranging their immunoglobulin
light chain loci. A period of clonal expansion in
large pre-B cells is shown. DJH, DH-JH segments
rearranged; VH-DJH, rearrangement of the VH-DH
segment; VDJH, heavy chain allele rearranged.
(B) ALL blast malleability and self-renewal. The
blast compartment for high- and low-risk ALL is
shown. Within these relatively narrow compart-
ments, blasts are able to upregulate and downre-
gulate components of the normal developmental
program, including accessing the self-renewal
program at all stages. There is, however, a block
to differentiation beyond the B precursor stage.
Genes demonstrated as being upregulated are
shown below the schema.that, unlike the more mature leukemic stem cells, survive chemo-
therapy and subsequently cause relapse.
This model of leukemia-propagating stem cells may prove
instrumental in unraveling the exact developmental hierarchy
within the different ALL subtypes, understanding the mecha-
nisms of in vivo chemotherapy resistance, and targeting new
drugs against the cells that cause chemotherapy resistance
and relapse.
EXPERIMENTAL PROCEDURES
Patient Samples
Bone marrow specimens were taken from children with ALL either at diagnosis
or at relapse (one patient, #14). Patients were under the care of the Department
of Pediatric Hematology and Oncology, University of Mu¨nster, Germany; the
Erasmus MC–Sophia Children’s Hospital, Rotterdam, The Netherlands; or
the Department of Paediatric Oncology, Royal Victoria Infirmary, Newcastle
upon Tyne, UK. Further patient information is given in the Supplemental Data.
The study was approved in Mu¨nster by the combined Ethics Committee of
the Medical Faculty, University of Mu¨nster and the regional chamber of physi-
cians (registration number 31 VVormoor) and in Newcastle by the Newcastle
and North Tyneside Ethics Committee 2 (REC reference number 06/Q0906/79).
Antibody Staining and Cell Sorting
Bone marrow freshly recovered from transplanted mice and thawed mononu-
clear cells (1.03 107 to 1.63 108 cells) from diagnostic bone marrow samples
were analyzed by flow cytometry. Cells were washed with RPMI 1640 medium
containing 20% fetal calf serum (FCS) and were stained with saturating
amounts of monoclonal antibodies (mAbs) against human cell-surface anti-
gens (Table S3) in a total volume of 0.5–1.0 ml for 20 min at 4C. Flow cytomet-
ric analysis of bone marrow samples from patients and engrafted mice was
performed on a FACSCalibur flow cytometer (BD Biosciences) using CellQuest
Pro software. For cell sorting experiments, cells were stained with anti-CD34
and anti-CD19 mAbs (Beckmann Coulter), and the cell concentration was ad-
justed to 107 cells per 1.5 ml in RPMI 1640 containing 20% FCS. Cell sorting
was performed on a FACSVantage SE cell sorter (BD Biosciences). Figure S6Ashows the gates used to isolate our populations. An example of the reanalyses
of the sorted populations is depicted in Figures S6B–S6D.
For experiments conducted in Newcastle, bone marrow samples were re-
suspended in 0.2% PBSA solution (BSA, Sigma; DPBS, Cambrex) and stained
with saturating amounts of mAbs against human cell-surface antigens (Table
S3). In addition, samples were labeled with anti-muCD45, a panleukocyte
marker, and anti-muTER119, an erythroid marker, to gate out the majority of
the murine background. Flow cytometric analysis was carried out on a FACS-
Canto II (BD Biosciences) using BD FACSDiva software. For cell sorting exper-
iments in Newcastle, samples were stained with anti-CD19 and anti-CD20
mAbs as well as mAbs against muCD45 and muTER119 and transplanted as
described below (for sorting gates, see Figure S5).
Animal Model
NOD/scid mice (JAX Mice stock name NOD.CB17-Prkdcscid/J mice) were pro-
vided by J.E. Dick (University of Toronto) (with permission from L.D.S.). The
NOD/scid mice were bred and maintained in individually ventilated cages at
the University of Mu¨nster as described previously (Baersch et al., 1997). Due
to a complex immunodeficiency involving B and T lymphocytes, natural killer
(NK) cells, macrophages, and the complement system, NOD/scid mice are al-
most completely unable to reject human xenotransplants (Shultz et al., 1995).
In general, unconditioned 8- to 16-week-old NOD/scid mice were used for the
experiments.
To further increase the sensitivity of the NOD/scid mouse model, during the
course of this study we began to NK cell deplete the mice with an anti-CD122
mAb. This treatment was shown to completely eradicate any residual NK cell
activity still present in these mice and for the first time allowed engraftment of
short-term repopulating human cells (McKenzie et al., 2005). A total of 89 of
199 mice (45%) were treated intraperitoneally with 135 ml of a 1.5 mg/ml anti-
CD122 mAb preparation 18–24 hr before transplantation. The anti-CD122
mAb was purified from the hybridoma cell line TM-b1 (gift of T. Tanaka, Osaka
University Medical Center, Osaka, Japan) (Tanaka et al., 1991). Purification
was performed using High-Trap protein G columns (Amersham Pharmacia).
The final preparation was quantified using the Bio-Rad Protein Assay (Bio-
Rad) with bovine g-globulin as standard.
For the additional experiments performed in Newcastle, NOD/scid IL2Rgnull
mice (JAX Mice stock name NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) that completely
lack any NK cell activity were used as recipients for human leukemicCancer Cell 14, 47–58, July 2008 ª2008 Elsevier Inc. 55
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performed under sterile conditions in a laminar flow hood.
Primary intrafemoral transplantations were usually performed with unsorted
patient samples. For serial transplantations, engrafted mice were humanely
killed, and both femurs and tibias were flushed with 1.5 ml RPMI medium con-
taining 20% FCS. Recovered bone marrow cells were stained with antibodies,
sorted, and transplanted.
Overall, a total of 338 mice were transplanted with human leukemic cells
(Mu¨nster cohort). 13 mice (4%) had to be excluded for technical reasons
(mainly failed intrafemoral injections). 60 mice were transplanted with cells
from the five nonengrafting leukemias (patients #2, 1365/01, 291/02, 384/05,
and 804/05). 66 mice were transplanted with unseparated bone marrow cells
from the eight engrafting leukemias (patients #1, 9, 12, 14, 15, 862/02, 1075/
04, and 1002/05). The remaining 199 mice were transplanted with ALL sub-
populations purified from engrafted leukemias. These 199 mice, of which
185 received at least the minimally engrafting cell dose of 23 103 cells, repre-
sent the primary experimental group for this study. For a complete list of all 199
transplantations performed, see Table S1.
The animal experiments in Mu¨nster were approved by the animal care com-
mittee of the local government (Bezirksregierung Mu¨nster, Aktenzeichen
50.0835.1.0 (G 25/2003)), and the transplantations in Newcastle were per-
formed under Home Office license PPL60/3554.
Intrafemoral Sample Injection and Bone Marrow Sampling
All leukemic cell samples were injected directly into the right femur of NOD/
scid mice as described previously (Mazurier et al., 2003). In brief, mice were
anesthetized with an isoflurane/oxygen gas mix (2.5% isoflurane and 0.5 l
O2 per minute), and 3 mg buprenorphine (Temgesic, Essex Pharma) or 50 ng
carprofen (Rimadyl, Pfizer) per 10 g body weight was subcutaneously injected
as an analgesic. The right femur was punctured with a 25 or 27G needle, and
sample volumes of up to 30 ml were subsequently injected with a 0.5 ml insulin
syringe (27 or 30G). To sample bone marrow, primary femoral puncture with
a 25 or 27G needle was followed by bone marrow aspiration with a 25G needle
into a syringe filled with 400 ml of 10% heparin (Liquemin, Hoffmann-La Roche
AG) in PBS buffer.
Preparation of Slides for Fluorescence In Situ Hybridization
Analysis and May-Gru¨nwald Giemsa Staining
Bone marrow cells for FISH analysis were prepared as described previously
(Hotfilder et al., 2002, 2005). In brief, 600–2000 cells from each population
were sorted into 20 ml drops of PBS that were placed on a grease-free glass
slide. Settling and adherence of the cells to the glass slide was facilitated by
incubating the slides for 10 min in a moist chamber. Excess PBS was carefully
removed with a paper towel. Ice-cold methanol/glacial acid (3:1 v/v) was used
to fix the cells, and the air-dried slides were analyzed by FISH. The histological
analysis of patient samples and mouse bone marrow was performed by May-
Gru¨nwald Giemsa staining of cytospin preparations.
FISH analyses for the TEL-AML1 gene fusions were performed on cytospin
preparations of sorted cells using the LSI TEL-AML1 ES Dual Color Transloca-
tion Probe Set (Vysis/Abbott). In addition, for detection of MLL rearrange-
ments, the LSI MLL Dual Color Break Apart Rearrangement Probe (Vysis/Ab-
bott) was applied. After a 2 min pepsin treatment (50 mg pepsin/ml 0.01 M
hydrochloric acid [pH 2.3], 37C), slides were washed once in PBS for 3 min,
fixed in 4% formaldehyde for 10 min at 4C, and, after two further washes
with PBS, dehydrated in a 70%–100% ethanol series. Air-dried slides and
probes were codenatured for 8 min on a 78C heat block and hybridized in
a moist chamber at 37C overnight. Posthybridization washes and analyses
of the cells were performed as described previously (Hotfilder et al., 2005).
Analysis of Patient-Specific Clonal Immunoglobulin Heavy
Chain Gene Rearrangements
This analysis was performed as described previously (van der Velden et al.,
2007). DNA from engrafted mouse bone marrow was extracted with a DNA ex-
traction kit (QIAGEN) (Verhagen et al., 1999). qRT-PCR was performed on
a LightCycler (Roche Diagnostics). For comparison and validation, initial diag-
nostic DNA samples of the patients were analyzed in parallel in the same
experiment as positive controls. Identical crossing points of both materials56 Cancer Cell 14, 47–58, July 2008 ª2008 Elsevier Inc.confirmed specificity, origin, and high tumor load of the engrafted human leu-
kemic cells in the mice.
Transcription Factor Expression
Primary patient bone marrow specimens were defrosted, labeled, and sorted
as described above. After sorting, cells were immediately resuspended in RLT
lysis buffer and homogenized using a 25G needle and syringe. Lysates were
stored at 80C prior to RNA extraction for qPCR and Affymetrix expression
analysis.
RNA extraction was performed using RNeasy Plus Micro extraction columns
(QIAGEN) according to the manufacturer’s instructions. cDNA synthesis was
performed using a RevertAid H Minus First Strand cDNA Synthesis Kit (Fer-
mentas UK) according to the manufacturer’s instructions. The starting reaction
mixture contained 50 ng total RNA and random hexamer primers.
cDNA was used immediately for quantitative RT-PCR using an ABI Prism
7900HT (Applied Biosystems). Primers were designed using Primer Express
software V2.0 (Applied Biosystems) to produce transcript-specific amplicons
for the gene of interest. Primer sequences are listed in the Supplemental Ex-
perimental Procedures. Reactions contained 5 ml Platinum SYBR qPCR
Supermix-UDG with ROX (Invitrogen Ltd.), 0.3 ml primer mix at 10 mM, 2.7 ml
RNase-free water, and 2 ml cDNA. Experiments were run in triplicate. Data
were analyzed using SDS 2.0 software (Applied Biosystems).
Affymetrix Expression Microarray Analysis
RNA from sorted cell populations was taken forward for expression microarray
analysis using the Affymetrix GeneChip HG-U133 Plus 2.0 array (Geneservice
Ltd.). Briefly, this process involves two cycles of cDNA synthesis and linear
amplification. cDNA is transcribed in vitro prior to biotinylation of cRNA using
the Affymetrix Two-Cycle Target Labeling kit. Biotinylated cRNA is subse-
quently hybridized to the array chip.
Data were processed by GC robust multiarray average (GCRMA) back-
ground adjustment normalization using the affy package supplied by BioCon-
ductor (http://www.bioconductor.org). Normalized data were analyzed for
genes showing >43 difference in expression between CD34+CD19+ and
CD34CD19+ populations.
ACCESSION NUMBERS
The microarray data are available online at ArrayExpress (http://www.ebi.ac.
uk/microarray-as/aer/) under the accession number E-MEXP-1522.
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plemental References, six figures, and three tables and can be found with this
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